LegoChem Biosciences
Wins 'Best ADC Platform Technology' at World ADC Awards 2023
- Clinches Prestigious Award for the 5 Consecutive Years, Recognized for Unparalleled Technological Expertise by
Industry Leaders
- Provides Insights into Pre-clinical and Clinical Progress on Trop2-ADC,
Claudin18.2-ADC, and More
LegoChem BioSciences Co., Ltd. (141080KS, referred
to as 'LEGOChem Bio') has been honored with the esteemed 'Best ADC Platform
Technology' award at the 'World ADC Awards 2023,' held on October 18th in San
Diego, USA. This category featured a competitive field of 7 contenders,
including Synaffix, WuxiXDC, and Ajinomoto. This remarkable achievement marks LegoChem Bio's 5th consecutive win, except for the previous year when it did
not participate, solidifying its reputation as a foremost industry leader, as
acclaimed by experts in the field.
Mr. Jae-wook Chae, Vice President and head of global business development at the
Boston branch, remarked, 'In light of the increasing concerns surrounding
ADC-related side effects, our ADC linker technology is gaining substantial
recognition as a pioneering solution to toxicity issues.' He further stated,
'Leveraging this technological prowess, we are currently engaged in discussions
with global pharmaceutical companies for diverse collaborative opportunities.'
CEO Mr. Yong-joo Kim recently announced the 'VISION 2030' strategy, outlining
the company's ambitious plans to actively secure 15 to 20 development pipelines
within the next 5 years, positioning LegoChem Bio as the Premier company in the industry.
During the conference, LegoChem Bio also delivered
verbal presentations on LCB84 (Trop2-ADC), on the edge of commencing its
first patient dosing in the United States, highlighting its minimal toxicity
and exceptional cancer targeting compared to competing drugs. Additionally,
the company unveiled non-clinical data for Claudin18.2-ADC, known as LCB02A,
marking its Debut release. This data showcased promising efficacy results in
patient-derived gastric and pancreatic cancer cell-based animal models. LegoChem
Bio aims to submit an Investigational New Drug (IND) application to the U.S.
FDA in the first half of 2025.